We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SAFC Appointed By Curalogic to Provide Chemical Development Services

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SAFC Appointed By Curalogic to Provide Chemical Development Services"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

SAFC, a member of the Sigma-Aldrich Group has announced that its SAFC Pharma business segment has been appointed by Curalogic A/S, a Danish biotechnology company, to provide protein isolation, extraction and purification services in connection with the development of products focused on Allergic Rhinitis.

Curalogic seeks to develop pharmaceuticals that are just as effective as injection immunotherapy and also offer patients the convenience and safety equal to that of the best symptomatic treatments.

Key products include a ragweed pollen extract that has just completed clinical Phase II trials, a grass pollen extract and cat extract currently in clinical Phase II, and a house dust mite extract that is in pre-clinical trials.

These compounds have the potential to treat a variety of allergies that significantly decrease the quality of life of millions of people today.

SAFC Pharma chemists working at the existing St. Louis protein purification and extraction facility will begin initial phases of the project.

These phases explore development of grass and house dust mite compounds to determine a suitable process for producing sufficient quantities of cGMP material for future clinical trials and commercial launch of these products.

 Subsequent phases of the Curalogic project will be transferred into SAFC’s new cGMP protein extraction and purification facility after its scheduled completion in April 2007.

Ove Pedersen, Executive Vice President of Development at Curalogic, said, “We are looking forward to working with SAFC in this field, as process development is such an important area for biological products. SAFC’s expertise in development of products derived from natural-sourced materials will be of great value to Curalogic.”

Frank Wicks, SAFC President, said, “This appointment by Curalogic for protein purification and contract research is the perfect fit for our new protein extraction and purification pilot plant facility currently under construction in St. Louis.

SAFC is a recognized leader in cGMP extraction and purification of therapeutic proteins from natural-sourced material, and we are pleased to act as Curalogic’s partner for the development and manufacturing of these allergy products.”